SK284655B6 - Farmaceutický prostriedok vo forme kapsuly alebo lisovanej tablety obsahujúci efavirenz a spôsob jeho výroby - Google Patents
Farmaceutický prostriedok vo forme kapsuly alebo lisovanej tablety obsahujúci efavirenz a spôsob jeho výroby Download PDFInfo
- Publication number
- SK284655B6 SK284655B6 SK1461-2000A SK14612000A SK284655B6 SK 284655 B6 SK284655 B6 SK 284655B6 SK 14612000 A SK14612000 A SK 14612000A SK 284655 B6 SK284655 B6 SK 284655B6
- Authority
- SK
- Slovakia
- Prior art keywords
- efavirenz
- capsule
- starch glycolate
- amount
- pharmaceutical composition
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 54
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 title claims abstract description 51
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229960003804 efavirenz Drugs 0.000 title claims abstract description 49
- 239000007891 compressed tablet Substances 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 17
- 238000000034 method Methods 0.000 title claims description 24
- 230000008569 process Effects 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 5
- 239000003826 tablet Substances 0.000 claims abstract description 38
- 229920003109 sodium starch glycolate Polymers 0.000 claims abstract description 37
- 239000008109 sodium starch glycolate Substances 0.000 claims abstract description 37
- 229940079832 sodium starch glycolate Drugs 0.000 claims abstract description 37
- 239000007884 disintegrant Substances 0.000 claims abstract description 35
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 13
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 238000005550 wet granulation Methods 0.000 claims description 34
- 239000000463 material Substances 0.000 claims description 25
- 239000004615 ingredient Substances 0.000 claims description 15
- 229920000881 Modified starch Polymers 0.000 claims description 9
- 235000019426 modified starch Nutrition 0.000 claims description 9
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 229960000913 crospovidone Drugs 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000004368 Modified starch Substances 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 238000009478 high shear granulation Methods 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000003801 milling Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 21
- 239000002245 particle Substances 0.000 description 18
- 238000004090 dissolution Methods 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000007909 solid dosage form Substances 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000007903 gelatin capsule Substances 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000001543 Corylus americana Nutrition 0.000 description 3
- 240000007582 Corylus avellana Species 0.000 description 3
- 235000007466 Corylus avellana Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- -1 clays Polymers 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960005168 croscarmellose Drugs 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000000485 Ranula Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940085001 efavirenz 100 mg Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8092598P | 1998-04-07 | 1998-04-07 | |
| PCT/US1999/007228 WO1999051239A1 (en) | 1998-04-07 | 1999-04-01 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK14612000A3 SK14612000A3 (sk) | 2001-07-10 |
| SK284655B6 true SK284655B6 (sk) | 2005-08-04 |
Family
ID=22160544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1461-2000A SK284655B6 (sk) | 1998-04-07 | 1999-04-01 | Farmaceutický prostriedok vo forme kapsuly alebo lisovanej tablety obsahujúci efavirenz a spôsob jeho výroby |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6238695B1 (cs) |
| EP (1) | EP1067936B1 (cs) |
| JP (1) | JP2002510634A (cs) |
| KR (1) | KR100634253B1 (cs) |
| CN (1) | CN1146419C (cs) |
| AR (1) | AR019031A1 (cs) |
| AT (1) | ATE223719T1 (cs) |
| AU (1) | AU756422B2 (cs) |
| BR (1) | BR9908810A (cs) |
| CA (1) | CA2321523C (cs) |
| CZ (1) | CZ300850B6 (cs) |
| DE (1) | DE69902893T2 (cs) |
| DK (1) | DK1067936T3 (cs) |
| EA (1) | EA003217B1 (cs) |
| EE (1) | EE04391B1 (cs) |
| ES (1) | ES2181417T3 (cs) |
| HU (1) | HU228498B1 (cs) |
| IL (1) | IL138078A (cs) |
| NO (1) | NO325824B1 (cs) |
| NZ (1) | NZ507566A (cs) |
| PL (1) | PL194309B1 (cs) |
| PT (1) | PT1067936E (cs) |
| SK (1) | SK284655B6 (cs) |
| TW (1) | TW576741B (cs) |
| UA (1) | UA72207C2 (cs) |
| WO (1) | WO1999051239A1 (cs) |
| ZA (1) | ZA200004313B (cs) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| EP1332757B1 (en) * | 1998-05-27 | 2012-06-13 | Merck Sharp & Dohme Corp. | Efavirenz compressed tablet formulation |
| US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
| HUP0102206A3 (en) * | 1998-06-11 | 2002-12-28 | Upjohn Co | Delavirdine tablet formulation |
| US7291352B2 (en) | 2001-10-03 | 2007-11-06 | Herbalscience Llc | Methods and compositions for oral delivery of Areca and mate' or theobromine |
| US20050069596A1 (en) * | 2001-10-03 | 2005-03-31 | Gow Robert T. | Compositions and methods comprising kava and anti-anxiety compounds |
| US7037524B2 (en) * | 2001-10-03 | 2006-05-02 | Herbalscience, Llc | Oral delivery of a botanical |
| US20050053678A1 (en) * | 2001-10-03 | 2005-03-10 | Gow Robert T. | Methods and compositions for betel nut chewing gum |
| AU2002359518A1 (en) * | 2001-11-27 | 2003-06-10 | Bristol-Myers Squibb Company | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US20050037025A1 (en) * | 2002-10-03 | 2005-02-17 | Gow Robert T. | Methods and compositions comprising kava and mate' or theobromine |
| EP1585527A1 (en) | 2003-01-14 | 2005-10-19 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| US8021682B2 (en) | 2004-08-13 | 2011-09-20 | Gallipot, Inc. | Palatable suspending vehicle for pharmaceutical ingredients |
| US20060099253A1 (en) * | 2004-10-20 | 2006-05-11 | Wyeth | Antibiotic product formulation |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| BRPI0614455A2 (pt) * | 2005-07-28 | 2011-03-29 | Isp Investments Inc | efavirenz amorfo e a produção deste |
| US20070059360A1 (en) * | 2005-07-29 | 2007-03-15 | Ashish Jaiswal | Water-dispersible anti-retroviral pharmaceutical compositions |
| WO2007068934A2 (en) * | 2005-12-14 | 2007-06-21 | Cipla Limited | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
| WO2008008120A1 (en) * | 2006-07-14 | 2008-01-17 | Fmc Corporation | Solid form |
| WO2008033487A2 (en) * | 2006-09-14 | 2008-03-20 | Chemlink Laboratories Llc | Method for preparing solid dosage forms that form a paste, cream or gel when diluted for final use |
| US20080152717A1 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments, Inc. | Amorphous valsartan and the production thereof |
| WO2008080037A2 (en) * | 2006-12-21 | 2008-07-03 | Isp Investments Inc. | Carotenoids of enhanced bioavailability |
| US10189957B2 (en) * | 2007-01-26 | 2019-01-29 | Isp Investments Llc | Formulation process method to produce spray dried products |
| US20080181961A1 (en) * | 2007-01-26 | 2008-07-31 | Isp Investments, Inc. | Amorphous oxcarbazepine and the production thereof |
| US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
| US20090088424A1 (en) * | 2007-08-17 | 2009-04-02 | Ilan Zalit | Methods and compositions for controlling the bioavailability of poorly soluble drugs |
| WO2010008719A2 (en) * | 2008-06-16 | 2010-01-21 | Schering Corporation | Oral pharmaceutical formulations of vla-4 antagonists |
| WO2010125572A1 (en) * | 2009-04-29 | 2010-11-04 | Hetero Research Foundation | Compressed tablets and capsules containing efavirenz |
| DK2531027T3 (en) | 2010-01-27 | 2015-07-20 | Viiv Healthcare Co | A therapeutic combination comprising dolutegravir, abacavir and lamivudine, |
| RU2012149115A (ru) * | 2010-04-20 | 2014-05-27 | Сипла Лимитед | Фармацевтическая композиция |
| CN104203275A (zh) | 2010-06-09 | 2014-12-10 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| CN102872019A (zh) * | 2012-09-17 | 2013-01-16 | 北京阜康仁生物制药科技有限公司 | 一种采用微粉化技术的依非韦伦制剂 |
| IN2013MU03370A (cs) | 2013-10-25 | 2015-09-25 | Cipla Ltd | |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| EP3334419A1 (en) | 2015-08-14 | 2018-06-20 | Sandoz AG | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz |
| CN114404377B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7084587A (en) | 1986-04-01 | 1987-10-20 | Upjohn Company, The | Methylprednisolone/sodium carboxymethyl starch tablet composition |
| HU205717B (en) * | 1989-04-28 | 1992-06-29 | Daiichi Seiyaku Co | Process for producing pharmaceutical composition against human immunodeficiency, comprising pyridionecarboxylic acid derivative |
| ES2106852T3 (es) * | 1992-07-08 | 1997-11-16 | Santen Oy | Composicion oftalmica que contiene hemihidrato de timolol. |
| US5665720A (en) | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| AU1694295A (en) * | 1994-01-28 | 1995-08-15 | Merck & Co., Inc. | Benzoxazinones as inhibitors of hiv reverse transcriptase |
| US5663467A (en) * | 1995-01-23 | 1997-09-02 | Merck & Co., Inc. | Synthesis of cyclopropylacetylene |
| IT1281502B1 (it) * | 1995-06-13 | 1998-02-18 | Sardinian Antiviral Research C | Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della |
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| PE20000559A1 (es) | 1998-05-27 | 2000-07-05 | Merck & Co Inc | Formulacion de tabletas comprimidas de efavirenz |
-
1999
- 1999-01-04 UA UA2000105657A patent/UA72207C2/uk unknown
- 1999-04-01 DK DK99916286T patent/DK1067936T3/da active
- 1999-04-01 EE EEP200000589A patent/EE04391B1/xx unknown
- 1999-04-01 CZ CZ20003571A patent/CZ300850B6/cs not_active IP Right Cessation
- 1999-04-01 CA CA002321523A patent/CA2321523C/en not_active Expired - Lifetime
- 1999-04-01 EP EP99916286A patent/EP1067936B1/en not_active Expired - Lifetime
- 1999-04-01 WO PCT/US1999/007228 patent/WO1999051239A1/en not_active Ceased
- 1999-04-01 AT AT99916286T patent/ATE223719T1/de active
- 1999-04-01 EA EA200001030A patent/EA003217B1/ru not_active IP Right Cessation
- 1999-04-01 PL PL99343421A patent/PL194309B1/pl unknown
- 1999-04-01 IL IL13807899A patent/IL138078A/xx not_active IP Right Cessation
- 1999-04-01 JP JP2000542010A patent/JP2002510634A/ja active Pending
- 1999-04-01 NZ NZ507566A patent/NZ507566A/xx not_active IP Right Cessation
- 1999-04-01 PT PT99916286T patent/PT1067936E/pt unknown
- 1999-04-01 KR KR1020007011091A patent/KR100634253B1/ko not_active Expired - Lifetime
- 1999-04-01 HU HU0101517A patent/HU228498B1/hu unknown
- 1999-04-01 SK SK1461-2000A patent/SK284655B6/sk not_active IP Right Cessation
- 1999-04-01 DE DE69902893T patent/DE69902893T2/de not_active Expired - Lifetime
- 1999-04-01 ES ES99916286T patent/ES2181417T3/es not_active Expired - Lifetime
- 1999-04-01 BR BR9908810-0A patent/BR9908810A/pt not_active Application Discontinuation
- 1999-04-01 CN CNB998048011A patent/CN1146419C/zh not_active Ceased
- 1999-04-01 AU AU34637/99A patent/AU756422B2/en not_active Expired
- 1999-04-06 US US09/286,902 patent/US6238695B1/en not_active Expired - Lifetime
- 1999-04-07 AR ARP990101586A patent/AR019031A1/es not_active Application Discontinuation
- 1999-06-09 TW TW088105520A patent/TW576741B/zh not_active IP Right Cessation
-
2000
- 2000-08-22 ZA ZA200004313A patent/ZA200004313B/xx unknown
- 2000-10-06 NO NO20005043A patent/NO325824B1/no not_active IP Right Cessation
-
2001
- 2001-04-02 US US09/824,071 patent/US6555133B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK284655B6 (sk) | Farmaceutický prostriedok vo forme kapsuly alebo lisovanej tablety obsahujúci efavirenz a spôsob jeho výroby | |
| EP1275391B1 (en) | Pharmaceutical compositions containing irbesartan and a diuretic | |
| JP2720932B2 (ja) | 経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤 | |
| EP1035838B1 (en) | Pharmaceutical suspension tablet compositions | |
| US8597666B2 (en) | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby | |
| EP1266657A1 (en) | Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride | |
| CZ225596A3 (en) | Film-coated tablets of paracetamol and domperidon | |
| AU2017244984A1 (en) | Oral preparation having exceptional elutability | |
| CA2563690A1 (en) | Pharmaceutical compositions comprising intra- and extra- granular fractions | |
| EA008585B1 (ru) | Капсулы флуконазола с улучшенным высвобождением | |
| JPH1121236A (ja) | ロキソプロフェン・ナトリウム固形製剤 | |
| US20050042279A1 (en) | Pharmaceutical formulation comprising more than 15% tamoxifen | |
| MXPA00009817A (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
| KR100396443B1 (ko) | 가용화된 펠로디핀 함유 지속성제제의 조성물 및 그의제조방법 | |
| WO2004024138A1 (ja) | ジオクチルソジウムスルホサクシネート配合固形製剤 | |
| CA2671778A1 (en) | Immediate release dosage form of bosentan and process of manufacturing such | |
| WO2010062996A2 (en) | Ribavirin composition | |
| NZ561044A (en) | Bi-layered modified release tablets for sustained release of guaifenesin combination drugs | |
| CZ2001227A3 (cs) | Biologicky zlepšené prostředky obsahující eprosartan v orální pevné dávkové formě |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiry of patent |
Expiry date: 20190401 |